Literature DB >> 33089719

An update on the improvement of patient eligibility with the use of new generation endografts for the treatment of abdominal aortic aneurysms.

Nikolaos Kontopodis1, Nikolaos Galanakis2, Ifigeneia Tzartzalou1, Emmanouil Tavlas1, Efstratios Georgakarakos3, Ioannins Dimopoulos1, Dimitrios Tsetis2, Christos V Ioannou1.   

Abstract

PURPOSE: Endovascular aneurysm repair (EVAR), performed within device instructions for use (IFU), offers improved outcomes. New endograft designs attempt to increase eligibility rates of abdominal aortic aneurysm (AAA) patients treated within device IFU. We aim to examine the anatomic suitability of the Ovation endograft in our AAA patients and compare it with the other contemporary devices. RESEARCH DESIGN AND METHODS: Three-hundred and seven consecutive elective AAA patients treated during a 5-year period were included. Patient-specific anatomic characteristics were based on endograft IFUs to determine eligibility rates of each system.
RESULTS: Two-hundred-twenty-five patients underwent EVAR and 82 open surgery. Ineligibility for device implantation was significantly lower for the Ovation iX system (32%) compared to other devices (AFX-2:49%, Altura:49%, Anaconda:54%, Endurant II:46%, Excluder:52%, Excluder Conformable:39%, Incraft:43%, E-Tegra:52%, Zenith-Alpha:52%; P-Value<0.001). The Alto system (next-generation Ovation) achieved an even lower ineligibility rate of 30% (P = 0.008). Short proximal aortic neck length followed by access vessel inadequacy were the primary reasons for ineligibility.
CONCLUSION: The Ovation-iX included more patients with anatomic characteristics within device IFUs resulting in improved eligibility rates compared with the rest of contemporary devices. Its evolution, the Alto system, further improves patient eligibility due to the inclusion of shorter aortic necks. EXPERT OPINION: The Ovation iX system presented a significantly better performance and was eligible for use in a greater number of patients in our series of elective AAA repairs, accommodating patient-specific aortic anatomies. Of course, performing EVAR within the endograft's IFU is important to achieve optimal and durable outcomes. The proximal neck length followed by the size of the access vessels are the two more common factors resulting in loss of eligibility. Except for overall eligibility rates, a case by case decision must be made on which is the most suitable device for each patient, based on the specific characteristics of its unique anatomy.

Entities:  

Keywords:  Aortic anatomy; aortic neck angulation; endograft sizing; endoleak; endovascular aneurysm repair; seal zone

Mesh:

Year:  2020        PMID: 33089719     DOI: 10.1080/17434440.2020.1841629

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  4 in total

1.  Endovascular Abdominal Aortic Aneurysm Repair With Ovation Alto Stent Graft: Protocol for the ALTAIR (ALTo endogrAft Italian Registry) Study.

Authors:  Gianmarco de Donato; Edoardo Pasqui; Pasqualino Sirignano; Francesco Talarico; Giancarlo Palasciano; Maurizio Taurino
Journal:  JMIR Res Protoc       Date:  2022-07-11

2.  Endovascular Juxtarenal Aortic Aneurysm Repair Using the ALTO Abdominal Stent Graft System: The First Case Series.

Authors:  Fotios O Efthymiou; Andreas L Tsimpoukis; Marianna A Papatsirou; Natasa K Kouri; Spyros I Papadoulas; Konstantinos M Nikolakopoulos; Stavros K Kakkos
Journal:  Vasc Specialist Int       Date:  2022-06-24

Review 3.  AAA Revisited: A Comprehensive Review of Risk Factors, Management, and Hallmarks of Pathogenesis.

Authors:  Veronika Kessler; Johannes Klopf; Wolf Eilenberg; Christoph Neumayer; Christine Brostjan
Journal:  Biomedicines       Date:  2022-01-02

4.  Early Experience with the New Ovation Alto Stent Graft in Endovascular Abdominal Aortic Aneurysm Repair.

Authors:  Gianmarco de Donato; Edoardo Pasqui; Claudia Panzano; Giuseppe Galzerano; Alessandro Cappelli; Giancarlo Palasciano
Journal:  EJVES Vasc Forum       Date:  2021-11-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.